APPLAUSE-IgAN Clinical Trial

Study at a Glance

Estimated Time Commitment


Age Eligibility: 18 years and older

Diagnosis Required

IgA nephropathy (IgAN)

Diseases Being Studied

Location: Texas Diabetes Institute

Currently there are no evidence-based disease-modifying pharmacotherapies for IgAN. The purpose of this clinical trial is to evaluate the superiority of LNP023 (a factor B inhibitor which works by damping the innate immune system) versus placebo on top of the maximally tolerated doses of an ACEi or ARB in slowing kidney disease progression and reduction in the protein in the urine.

Location: Texas Diabetes Institute

Meet Your Clinical Research Team

Contact us

Principal Investigator: Dr. Shweta Bansal; Sponsor: Novartis Pharmaceuticals

Dr. Shweta Bansal; Sponsor: Novartis Pharmaceuticals